Esperion Therapeutics, Inc. is a biopharmaceutical company that develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). The company's lead product candidate is bempedoic acid, an inhibitor of ATP Citrate Lyase, which is in Phase III long-term safety and tolerability study to treat patients with hypercholesterolemia. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.